These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

67 related articles for article (PubMed ID: 18451188)

  • 1. Double-blind randomized treatment of poststroke depression using nefiracetam.
    Robinson RG; Jorge RE; Clarence-Smith K
    J Neuropsychiatry Clin Neurosci; 2008; 20(2):178-84. PubMed ID: 18451188
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Double-blind treatment of apathy in patients with poststroke depression using nefiracetam.
    Robinson RG; Jorge RE; Clarence-Smith K; Starkstein S
    J Neuropsychiatry Clin Neurosci; 2009; 21(2):144-51. PubMed ID: 19622685
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Randomized, Placebo-Controlled, Double-Blind Efficacy Study of Nefiracetam to Treat Poststroke Apathy.
    Starkstein SE; Brockman S; Hatch KK; Bruce DG; Almeida OP; Davis WA; Robinson RG
    J Stroke Cerebrovasc Dis; 2016 May; 25(5):1119-1127. PubMed ID: 26915605
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early fluoxetine treatment of post-stroke depression--a three-month double-blind placebo-controlled study with an open-label long-term follow up.
    Fruehwald S; Gatterbauer E; Rehak P; Baumhackl U
    J Neurol; 2003 Mar; 250(3):347-51. PubMed ID: 12638027
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of cognitive impairment after poststroke depression : a double-blind treatment trial.
    Kimura M; Robinson RG; Kosier JT
    Stroke; 2000 Jul; 31(7):1482-6. PubMed ID: 10884441
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized controlled trial of duloxetine versus placebo in the treatment of nonmajor chronic depression.
    Hellerstein DJ; Stewart JW; McGrath PJ; Deliyannides DA; Batchelder ST; Black SR; Withers A; O'Shea D; Chen Y
    J Clin Psychiatry; 2012 Jul; 73(7):984-91. PubMed ID: 22901348
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of methylphenidate on fatigue and depression: a randomized, double-blind, placebo-controlled trial.
    Kerr CW; Drake J; Milch RA; Brazeau DA; Skretny JA; Brazeau GA; Donnelly JP
    J Pain Symptom Manage; 2012 Jan; 43(1):68-77. PubMed ID: 22208450
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BDNF, interleukin-6, and salivary cortisol levels in depressed patients treated with desvenlafaxine.
    Ninan PT; Shelton RC; Bao W; Guico-Pabia CJ
    Prog Neuropsychopharmacol Biol Psychiatry; 2014 Jan; 48():86-91. PubMed ID: 24096053
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preliminary randomized, double-blind, placebo-controlled trial of pramipexole added to mood stabilizers for treatment-resistant bipolar depression.
    Goldberg JF; Burdick KE; Endick CJ
    Am J Psychiatry; 2004 Mar; 161(3):564-6. PubMed ID: 14992985
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Achieving remission with venlafaxine and fluoxetine in major depression: its relationship to anxiety symptoms.
    Davidson JR; Meoni P; Haudiquet V; Cantillon M; Hackett D
    Depress Anxiety; 2002; 16(1):4-13. PubMed ID: 12203668
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies.
    Tourian KA; Padmanabhan SK; Groark J; Brisard C; Farrington D
    Clin Ther; 2009 Jun; 31 Pt 1():1405-23. PubMed ID: 19698901
    [TBL] [Abstract][Full Text] [Related]  

  • 12. B-vitamins reduce the long-term risk of depression after stroke: The VITATOPS-DEP trial.
    Almeida OP; Marsh K; Alfonso H; Flicker L; Davis TM; Hankey GJ
    Ann Neurol; 2010 Oct; 68(4):503-10. PubMed ID: 20976769
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Repetitive transcranial magnetic stimulation as treatment of poststroke depression: a preliminary study.
    Jorge RE; Robinson RG; Tateno A; Narushima K; Acion L; Moser D; Arndt S; Chemerinski E
    Biol Psychiatry; 2004 Feb; 55(4):398-405. PubMed ID: 14960293
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevention of poststroke depression with milnacipran in patients with acute ischemic stroke: a double-blind randomized placebo-controlled trial.
    Tsai CS; Wu CL; Chou SY; Tsang HY; Hung TH; Su JA
    Int Clin Psychopharmacol; 2011 Sep; 26(5):263-7. PubMed ID: 21811172
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A controlled trial of piracetam in intellectually impaired patients with Parkinson's disease.
    Sano M; Stern Y; Marder K; Mayeux R
    Mov Disord; 1990; 5(3):230-4. PubMed ID: 2388639
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [A psychotropic drug treatment of psychiatric symptoms after stroke].
    Shimoda K; Kimura M
    Nihon Rinsho; 2012 Jan; 70(1):89-93. PubMed ID: 22413499
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Two 6-week, randomized, double-blind, placebo-controlled studies of ziprasidone in outpatients with bipolar I depression: did baseline characteristics impact trial outcome?
    Lombardo I; Sachs G; Kolluri S; Kremer C; Yang R
    J Clin Psychopharmacol; 2012 Aug; 32(4):470-8. PubMed ID: 22722504
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A double-blind, placebo-controlled pilot study of quetiapine for depressed adolescents with bipolar disorder.
    DelBello MP; Chang K; Welge JA; Adler CM; Rana M; Howe M; Bryan H; Vogel D; Sampang S; Delgado SV; Sorter M; Strakowski SM
    Bipolar Disord; 2009 Aug; 11(5):483-93. PubMed ID: 19624387
    [TBL] [Abstract][Full Text] [Related]  

  • 19. General pharmacological profile of the new cognition-enhancing agent nefiracetam.
    Kitano Y; Makino M; Usui C; Takasuna K; Kasai Y; Hirohashi M; Tamura K; Takayama S; Kojima H; Iizuka H
    Arzneimittelforschung; 1994 Feb; 44(2A):199-210. PubMed ID: 8018090
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized, double-blind, placebo-controlled trial of augmentation with an extended release formulation of methylphenidate in outpatients with treatment-resistant depression.
    Patkar AA; Masand PS; Pae CU; Peindl K; Hooper-Wood C; Mannelli P; Ciccone P
    J Clin Psychopharmacol; 2006 Dec; 26(6):653-6. PubMed ID: 17110825
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.